Showing information for HMDB0002013 ('butyryl-carnitine')

Metabolite information
HMDB ID HMDB0002013
Synonyms
Butylcarnitine
Butyryl-L-carnitine
Butyrylcarnitine
Celiac
Cellular membrane
Coeliac disease
Csf
Cytoplasma
Digestion
Extracellular region
Fauna
L-Carnitine butyryl ester
Lipid metabolic process
Membrane integrity agent
Membrane stability agent
N-Butyryl-L-[-]-carnitin
O-Butanoyl-[R]-carnitine
O-Butanoyl-carnitine
O-Butanoylcarnitine
Signal transduction
Surface-active agent
Vlcad
Vlchad
[3R]-3-[Butyryloxy]-4-[trimethylammonio]butanoate
[3R]-3-[Butyryloxy]-4-[trimethylammonio]butanoic acid
Chemical formula C11H21NO4
IUPAC name
(3R)-3-(butanoyloxy)-4-(trimethylazaniumyl)butanoate
CAS registry number 25576-40-3
Monisotopic molecular weight 231.14705816

Chemical taxonomy
Super class Lipids and lipid-like molecules
Class Fatty Acyls
Sub class Fatty acid esters

Biological properties
Pahtways
Author-emphasized biomarker in the paper(s)

Lung cancer metabolomics studies that identify HMDB0002013 ('butyryl-carnitine')

Reference Country Specimen Marker function Participants (Case) Participants (Control)
Cancer type Stage Number Gender (M,F) Age mean (range) (M/F) Smoking status Type Number Gender (M,F) Age mean (range) (M/F) Smoking status
Mazzone et al. 2016 – serum – adenocarcinoma, squamous cell carcinoma I, II, III 94 55.3%, 44.7% 68.7 – at-risk controls 190 50.5%, 49.5% 66.2 –
Callejón-Leblic et al. 2019 – blood diagnosis NSCLC, SCLC II, III, IV 30 25, 5 67 ± 12 former, current, non-smoker healthy 30 14, 16 56 ± 14 former, non-smoker
Moreno et al. 2018 – tissue therapy, diagnosis adenocarcinoma I, II, III 33 24, 9 62.11 ± 9.73 – tumor vs. adjacent normal tissue 33 24, 9 62.11 ± 9.73 –
Moreno et al. 2018 – tissue therapy, diagnosis squamous cell carcinoma I, II, III 35 35, 0 68.71 ± 7.46 – tumor vs. adjacent normal tissue 35 35, 0 68.71 ± 7.46 –
Reference Chromatography Ion source Positive/Negative mode Mass analyzer Identification level
Mazzone et al. 2016 LC ESI positive linear ion-trap MS/MS
Callejón-Leblic et al. 2019 DI ESI positive Q-TOF MS/MS
Moreno et al. 2018 LC, GC ESI, EI positive, negative LC: linear ion‐trap, GC: single‐quadrupole LC: MS/MS
Moreno et al. 2018 LC, GC ESI, EI positive, negative LC: linear ion‐trap, GC: single‐quadrupole LC: MS/MS
Reference Data processing software Database search
Mazzone et al. 2016 Metabolon LIMS system Metabolon LIMS system
Callejón-Leblic et al. 2019 – HMDB, Metlin
Moreno et al. 2018 – KEGG, HMDB
Moreno et al. 2018 – KEGG, HMDB
Reference Difference method Mean concentration (case) Mean concentration (control) Fold change (case/control) P-value FDR VIP
Mazzone et al. 2016 two- sample independent t test 1.175564± 0.6088263 1.088488± 0.5128193 1.07999720713504 0.2068233 0.317373142 –
Callejón-Leblic et al. 2019 PCA, PLS-DA, one-way ANOVA – – 2.28 0.044 – 1.26
Moreno et al. 2018 paired two‐sample t‐test, PLS-DA – – 1.65133920821019 0.0000721387316736048 0.00025747075776189 –
Moreno et al. 2018 paired two‐sample t‐test, PLS-DA – – 2.18182715364577 0.00000000276255937047508 0.0000000117888897199953 –
Reference Classification method Cutoff value AUROC 95%CI Sensitivity (%) Specificity (%) Accuracy (%)
Mazzone et al. 2016 – – – – – –
Callejón-Leblic et al. 2019 ROC curve – 0.66 – – –
Moreno et al. 2018 – – – – – –
Moreno et al. 2018 – – – – – –